Baidu
map

Nucleic Acids Res:上海交大与IBM合作结硕果:医药大数据助力个体化医疗

2014-07-14 佚名 不详

  上海交大等机构合作构建的药物相互作用搜索引擎界面截图 经过多年的努力,上海交通大学Bio-X研究院联合美国IBM沃森研究院、哈佛大学、加州大学伯克利分校等医药大数据前沿机构的研究人员通力协作,共同构建了基于医药大数据的药物互相作用搜索引擎,进而在个体化用药研究方面取得重要进展。部分研究成果已发表在近期的《核酸研究》(影响因子8.3)上。 在此项研究中,研究人员利用化合物-蛋

 

上海交大等机构合作构建的药物相互作用搜索引擎界面截图

经过多年的努力,上海交通大学Bio-X研究院联合美国IBM沃森研究院、哈佛大学、加州大学伯克利分校等医药大数据前沿机构的研究人员通力协作,共同构建了基于医药大数据的药物互相作用搜索引擎,进而在个体化用药研究方面取得重要进展。部分研究成果已发表在近期的《核酸研究》(影响因子8.3)上。

在此项研究中,研究人员利用化合物-蛋白互作组(Chemical-ProteinInteractome, CPI)的海量数据在超级计算机上模拟药物相互作用。工作首先模拟FDA所批药物已知的相互作用指纹图谱,通过改进了的大数据挖掘算法,比较用户提交分子的指纹图谱来预测潜在药物互作,从而及时预测用药风险。和同类预测比较后,研究人员发现该引擎的计算精度处于领先地位,因此可为规避基于药物互作的药物不良反应提供了重要信息,从而有助于实现个性化用药。

该项研究得到了研究院相关领导的支持,继而由前美国FDA访问学者、杨仑博士构思和领导。主要参与单位还包括了医药大数据研究前沿的诸多知名机构,如美国IBM沃森研究院、哈佛大学Dana-Farber肿瘤研究所、加州大学伯克利分校和复旦大学等。上海交通大学Bio-X研究院为第一单位,罗衡为论文的首要第一作者,美国IBM沃森研究院的Ping Zhang博士为论文的并列第一作者, Hui Huang为第二作者。

原始出处

Luo H1, Zhang P2, Huang H3, Huang J4, Kao E5, Shi L6, He L3, Yang L7.DDI-CPI, a server that predicts drug-drug interactions through implementing the chemical-protein interactome.Nucleic Acids Res. 2014 Jul;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1911410, encodeId=b90f1911410a1, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 21 09:10:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929103, encodeId=b32219291033a, content=<a href='/topic/show?id=19d521285fb' target=_blank style='color:#2F92EE;'>#个体化医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21285, encryptionId=19d521285fb, topicName=个体化医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Wed Jul 23 15:10:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991566, encodeId=8aa1199156673, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Aug 12 20:10:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408646, encodeId=cc2214086460c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435280, encodeId=dd9b143528030, content=<a href='/topic/show?id=9a5c212e88f' target=_blank style='color:#2F92EE;'>#个体化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21278, encryptionId=9a5c212e88f, topicName=个体化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489920, encodeId=d34c14899201c, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553808, encodeId=fe81155380885, content=<a href='/topic/show?id=0ba81988692' target=_blank style='color:#2F92EE;'>#上海交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19886, encryptionId=0ba81988692, topicName=上海交大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a6414444709, createdName=gao_jian4222, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]
    2014-12-21 wodejia-dayu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1911410, encodeId=b90f1911410a1, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 21 09:10:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929103, encodeId=b32219291033a, content=<a href='/topic/show?id=19d521285fb' target=_blank style='color:#2F92EE;'>#个体化医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21285, encryptionId=19d521285fb, topicName=个体化医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Wed Jul 23 15:10:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991566, encodeId=8aa1199156673, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Aug 12 20:10:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408646, encodeId=cc2214086460c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435280, encodeId=dd9b143528030, content=<a href='/topic/show?id=9a5c212e88f' target=_blank style='color:#2F92EE;'>#个体化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21278, encryptionId=9a5c212e88f, topicName=个体化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489920, encodeId=d34c14899201c, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553808, encodeId=fe81155380885, content=<a href='/topic/show?id=0ba81988692' target=_blank style='color:#2F92EE;'>#上海交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19886, encryptionId=0ba81988692, topicName=上海交大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a6414444709, createdName=gao_jian4222, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1911410, encodeId=b90f1911410a1, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 21 09:10:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929103, encodeId=b32219291033a, content=<a href='/topic/show?id=19d521285fb' target=_blank style='color:#2F92EE;'>#个体化医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21285, encryptionId=19d521285fb, topicName=个体化医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Wed Jul 23 15:10:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991566, encodeId=8aa1199156673, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Aug 12 20:10:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408646, encodeId=cc2214086460c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435280, encodeId=dd9b143528030, content=<a href='/topic/show?id=9a5c212e88f' target=_blank style='color:#2F92EE;'>#个体化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21278, encryptionId=9a5c212e88f, topicName=个体化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489920, encodeId=d34c14899201c, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553808, encodeId=fe81155380885, content=<a href='/topic/show?id=0ba81988692' target=_blank style='color:#2F92EE;'>#上海交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19886, encryptionId=0ba81988692, topicName=上海交大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a6414444709, createdName=gao_jian4222, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]
    2014-08-12 xlxchina
  4. [GetPortalCommentsPageByObjectIdResponse(id=1911410, encodeId=b90f1911410a1, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 21 09:10:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929103, encodeId=b32219291033a, content=<a href='/topic/show?id=19d521285fb' target=_blank style='color:#2F92EE;'>#个体化医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21285, encryptionId=19d521285fb, topicName=个体化医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Wed Jul 23 15:10:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991566, encodeId=8aa1199156673, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Aug 12 20:10:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408646, encodeId=cc2214086460c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435280, encodeId=dd9b143528030, content=<a href='/topic/show?id=9a5c212e88f' target=_blank style='color:#2F92EE;'>#个体化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21278, encryptionId=9a5c212e88f, topicName=个体化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489920, encodeId=d34c14899201c, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553808, encodeId=fe81155380885, content=<a href='/topic/show?id=0ba81988692' target=_blank style='color:#2F92EE;'>#上海交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19886, encryptionId=0ba81988692, topicName=上海交大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a6414444709, createdName=gao_jian4222, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]
    2014-07-16 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=1911410, encodeId=b90f1911410a1, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 21 09:10:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929103, encodeId=b32219291033a, content=<a href='/topic/show?id=19d521285fb' target=_blank style='color:#2F92EE;'>#个体化医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21285, encryptionId=19d521285fb, topicName=个体化医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Wed Jul 23 15:10:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991566, encodeId=8aa1199156673, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Aug 12 20:10:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408646, encodeId=cc2214086460c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435280, encodeId=dd9b143528030, content=<a href='/topic/show?id=9a5c212e88f' target=_blank style='color:#2F92EE;'>#个体化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21278, encryptionId=9a5c212e88f, topicName=个体化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489920, encodeId=d34c14899201c, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553808, encodeId=fe81155380885, content=<a href='/topic/show?id=0ba81988692' target=_blank style='color:#2F92EE;'>#上海交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19886, encryptionId=0ba81988692, topicName=上海交大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a6414444709, createdName=gao_jian4222, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1911410, encodeId=b90f1911410a1, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 21 09:10:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929103, encodeId=b32219291033a, content=<a href='/topic/show?id=19d521285fb' target=_blank style='color:#2F92EE;'>#个体化医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21285, encryptionId=19d521285fb, topicName=个体化医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Wed Jul 23 15:10:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991566, encodeId=8aa1199156673, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Aug 12 20:10:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408646, encodeId=cc2214086460c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435280, encodeId=dd9b143528030, content=<a href='/topic/show?id=9a5c212e88f' target=_blank style='color:#2F92EE;'>#个体化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21278, encryptionId=9a5c212e88f, topicName=个体化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489920, encodeId=d34c14899201c, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553808, encodeId=fe81155380885, content=<a href='/topic/show?id=0ba81988692' target=_blank style='color:#2F92EE;'>#上海交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19886, encryptionId=0ba81988692, topicName=上海交大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a6414444709, createdName=gao_jian4222, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]
    2014-07-16 tulenzi
  7. [GetPortalCommentsPageByObjectIdResponse(id=1911410, encodeId=b90f1911410a1, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Dec 21 09:10:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929103, encodeId=b32219291033a, content=<a href='/topic/show?id=19d521285fb' target=_blank style='color:#2F92EE;'>#个体化医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21285, encryptionId=19d521285fb, topicName=个体化医疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Wed Jul 23 15:10:00 CST 2014, time=2014-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991566, encodeId=8aa1199156673, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Aug 12 20:10:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408646, encodeId=cc2214086460c, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435280, encodeId=dd9b143528030, content=<a href='/topic/show?id=9a5c212e88f' target=_blank style='color:#2F92EE;'>#个体化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21278, encryptionId=9a5c212e88f, topicName=个体化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489920, encodeId=d34c14899201c, content=<a href='/topic/show?id=f91c93134e' target=_blank style='color:#2F92EE;'>#IBM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9313, encryptionId=f91c93134e, topicName=IBM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0288649873, createdName=tulenzi, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553808, encodeId=fe81155380885, content=<a href='/topic/show?id=0ba81988692' target=_blank style='color:#2F92EE;'>#上海交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19886, encryptionId=0ba81988692, topicName=上海交大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a6414444709, createdName=gao_jian4222, createdTime=Wed Jul 16 00:10:00 CST 2014, time=2014-07-16, status=1, ipAttribution=)]

相关资讯

大数据时代,“球”神问卜变成科学

2014巴西世界杯开战在即,足坛32列强的比赛盛宴亦将马上呈现。对于大多数球迷而言,能够喝着啤酒看比赛无疑是最幸福的事情。然而,如果稍加主动地抢占科技“前排”,今年的世界杯也许不只是观看一场足球盛宴,更能全情参与,“指点”世界杯。 大数据预测东道主夺冠 最终谁将夺冠?在世界杯决赛结束之前,每个球迷都会对这个问题津津乐道。如果不是某个球队的铁杆粉丝,利用大数据预测各国家队的夺冠概率会让世界杯的谈

CFDA上线APP FDA开放大数据

6月4日,“国家食药监管”App正式上线,公众免费下载手机客户端后,就能通过手机轻松浏览国家食品药品监管总局官方网站发布的信息,随时随地查询食品药品基础数据,方便快捷地掌握各项许可进度。 该版APP设3屏27个栏目,囊括资讯新闻、数据查询等功能:其栏目设置和网站基本对应,但该APP版本支持用户订制个性化页面的功能,并可将资讯内容在微博、微信等平台一键分享。 据CFDA官方网站介绍,数据

大数据时代,我们应该享有“被遗忘的权利”

30多年前,著名未来学家阿尔文·托夫勒(Alvin Toffler)出版了一本划时代的巨著《第三次浪潮》(The Third Wave)。这本书将人类社会划分为三个阶段:第一次浪潮为农业阶段,约1万年前开始;第二阶段为工业阶段,17世纪末开始;第三阶段为信息化(或者服务业)阶段,从20世纪50年代后期开始,并将大数据称为“第三次浪潮的华彩乐章”。不过,“大数据”真正成为互联网信息技术行业的流行

李兰娟:云计算与大数据将成为医疗改革利器

“第六届中国云计算大会”将于2014年5月20-23日在北京国家会议中心隆重召开。本次大会将历时四天,内容更加精彩,预计参会者将大大超过上一届的12000多人次。每届中国云计算大会,都有两院院士的精彩演讲。本届大会上,李德毅、怀进鹏、倪光南、李伯虎、杨学军、张尧学、李未、梅宏、高文、李兰娟等10位两院院士将集体亮相,与广大参会者共同把脉云计算与大数据的未来技术发展和应用方向。大会召开前夕,CSDN

肿瘤大数据公司Flatiron获google 1.3亿美元投资

Flatiron Health主要业务是开发收集临床记录、缴费记录和基因组等数据的软件。 5月8日消息,谷歌风投(Google Ventures)日前展开了公司历史上最大一笔医疗软件投资,该公司将为大数据肿瘤医疗行业创业公司Flatiron Health提供1.3亿美元融资,并希望今后医生能够根据该公司所收集的数据作出更加精确的临床诊断。早期风险投资公司First Round Capital、

百度开放的大数据引擎将如何改变医疗和交通

还记得百度斥巨资建立的致力于人工智能技术开发的深度学习研究院么?接下来,它将不再只为百度自己所用了。而且,百度的其它大数据技术也将会与它一起走出象牙塔。 昨天,百度正式开放了其名为“大数据引擎”的技术体系。简单来说,“大数据引擎”指的是对大规模的数据进行收集、存储、计算、挖掘和管理的一套系统。通过百度的深度学习技术和数据建模技术,能够让数据分析变得更实时和精准。此前,百度已经将这些技术用在了自

Baidu
map
Baidu
map
Baidu
map